Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 3
Submit an article Journal homepage
1,622
Views
41
CrossRef citations to date
0
Altmetric
Reviews

Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses

Ponraj Prabakaran Protein Interactions, CCRNP, NCI-Frederick, NIH, Building 469, 150B, P.O. Box B, Miller Drive, Frederick, MD 21702 1201, USA +1 301 846 1352; +1 301 846 5598; [email protected]; Duke University Medical Center, Duke Human Vaccine Institute, 106 Research Drive, MSRBII, 3013, Box 103020 DUMC, Durham, NC 27710, USA [email protected]; *These authors contributed equally to this work
,
Zhongyu Zhu Protein Interactions, CCRNP, NCI-Frederick, NIH, Building 469, 150B, P.O. Box B, Miller Drive, Frederick, MD 21702 1201, USA +1 301 846 1352; +1 301 846 5598; [email protected]; BRP, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD 21702, USA; *These authors contributed equally to this work
,
Xiaodong Xiao Protein Interactions, CCRNP, NCI-Frederick, NIH, Building 469, 150B, P.O. Box B, Miller Drive, Frederick, MD 21702 1201, USA +1 301 846 1352; +1 301 846 5598; [email protected]
,
Arya Biragyn Immunotherapeutics Unit, National Institute on Aging, Baltimore, MD 21224, USA
,
Antony S Dimitrov Profectus BioSciences, Inc., 6411 Beckley Street, Baltimore, MD 21224, USA; Uniformed Services University, Department of Microbiology and Immunology, Bethesda, MD 20814, USA
,
Christopher C Broder Uniformed Services University, Department of Microbiology and Immunology, Bethesda, MD 20814, USA
&
Dimiter S Dimitrov Protein Interactions, CCRNP, NCI-Frederick, NIH, Building 469, 150B, P.O. Box B, Miller Drive, Frederick, MD 21702 1201, USA +1 301 846 1352; +1 301 846 5598; [email protected]
 show all
Pages 355-368 | Published online: 08 Apr 2009
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Background: Recently, several potent human monoclonal antibodies (hmAbs) targeting the severe acute respiratory syndrome-associated coronavirus (SARS CoV) S glycoproteins, as well as the first fully human mAbs against two other paramyxoviruses, Hendra virus (HeV) and Nipah virus (NiV) have been discovered. Objective: To examine, compare and contrast the functional characteristics of hmAbs with potential for prophylaxis and treatment of diseases caused by SARS CoV, HeV and NiV. Methods: A review of relevant literature. Results/conclusions: Structural analyses have provided insights into the molecular mechanisms of receptor recognition and antibody neutralization, and suggested that these antibodies alone or in combination could fight the viruses' heterogeneity and mutability, which is a major problem in the development of effective therapeutic agents against viruses, including therapeutic antibodies.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 960.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.